GB201707864D0 - Platinum-reistant cancer treatment - Google Patents

Platinum-reistant cancer treatment

Info

Publication number
GB201707864D0
GB201707864D0 GBGB1707864.3A GB201707864A GB201707864D0 GB 201707864 D0 GB201707864 D0 GB 201707864D0 GB 201707864 A GB201707864 A GB 201707864A GB 201707864 D0 GB201707864 D0 GB 201707864D0
Authority
GB
United Kingdom
Prior art keywords
reistant
platinum
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1707864.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Priority to GBGB1707864.3A priority Critical patent/GB201707864D0/en
Publication of GB201707864D0 publication Critical patent/GB201707864D0/en
Priority to TW107116652A priority patent/TW201900176A/zh
Priority to US16/613,912 priority patent/US20200352945A1/en
Priority to AU2018268400A priority patent/AU2018268400B2/en
Priority to MX2019013665A priority patent/MX2019013665A/es
Priority to NZ758037A priority patent/NZ758037A/en
Priority to KR1020247032300A priority patent/KR20240148941A/ko
Priority to CA3062552A priority patent/CA3062552C/en
Priority to PCT/IB2018/053428 priority patent/WO2018211433A1/en
Priority to CN201880030434.2A priority patent/CN110603042A/zh
Priority to EP18730117.1A priority patent/EP3624803A1/en
Priority to JP2019562653A priority patent/JP7627393B2/ja
Priority to KR1020197032543A priority patent/KR20200003811A/ko
Priority to ARP180101299A priority patent/AR111803A1/es
Priority to SG11201909859R priority patent/SG11201909859RA/en
Priority to MX2023005295A priority patent/MX2023005295A/es
Priority to US16/810,160 priority patent/US11026948B2/en
Priority to US17/306,052 priority patent/US12128045B2/en
Priority to JP2023018285A priority patent/JP7658995B2/ja
Priority to AU2024205462A priority patent/AU2024205462B2/en
Priority to US18/893,063 priority patent/US20250152587A1/en
Priority to JP2025052922A priority patent/JP2025098190A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
GBGB1707864.3A 2017-05-16 2017-05-16 Platinum-reistant cancer treatment Ceased GB201707864D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1707864.3A GB201707864D0 (en) 2017-05-16 2017-05-16 Platinum-reistant cancer treatment
SG11201909859R SG11201909859RA (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
EP18730117.1A EP3624803A1 (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
KR1020197032543A KR20200003811A (ko) 2017-05-16 2018-05-16 백금-내성 암 치료제
AU2018268400A AU2018268400B2 (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
MX2019013665A MX2019013665A (es) 2017-05-16 2018-05-16 Tratamiento contra el cancer resistente a platino.
NZ758037A NZ758037A (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
KR1020247032300A KR20240148941A (ko) 2017-05-16 2018-05-16 백금-내성 암 치료제
CA3062552A CA3062552C (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
PCT/IB2018/053428 WO2018211433A1 (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
CN201880030434.2A CN110603042A (zh) 2017-05-16 2018-05-16 铂类抗药性癌症治疗
TW107116652A TW201900176A (zh) 2017-05-16 2018-05-16 鉑類耐藥性癌症治療
JP2019562653A JP7627393B2 (ja) 2017-05-16 2018-05-16 白金耐性癌の治療
US16/613,912 US20200352945A1 (en) 2017-05-16 2018-05-16 Platinum-resistant cancer treatment
ARP180101299A AR111803A1 (es) 2017-05-16 2018-05-16 Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino
MX2023005295A MX2023005295A (es) 2017-05-16 2019-11-14 Tratamiento contra el cancer resistente a platino.
US16/810,160 US11026948B2 (en) 2017-05-16 2020-03-05 Platinum-resistant cancer treatment
US17/306,052 US12128045B2 (en) 2017-05-16 2021-05-03 Platinum-resistant cancer treatment
JP2023018285A JP7658995B2 (ja) 2017-05-16 2023-02-09 白金耐性癌の治療
AU2024205462A AU2024205462B2 (en) 2017-05-16 2024-08-02 Platinum-resistant cancer treatment
US18/893,063 US20250152587A1 (en) 2017-05-16 2024-09-23 Platinum-resistant cancer treatment
JP2025052922A JP2025098190A (ja) 2017-05-16 2025-03-27 白金耐性癌の治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1707864.3A GB201707864D0 (en) 2017-05-16 2017-05-16 Platinum-reistant cancer treatment

Publications (1)

Publication Number Publication Date
GB201707864D0 true GB201707864D0 (en) 2017-06-28

Family

ID=59201547

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1707864.3A Ceased GB201707864D0 (en) 2017-05-16 2017-05-16 Platinum-reistant cancer treatment

Country Status (13)

Country Link
US (4) US20200352945A1 (https=)
EP (1) EP3624803A1 (https=)
JP (3) JP7627393B2 (https=)
KR (2) KR20240148941A (https=)
CN (1) CN110603042A (https=)
AR (1) AR111803A1 (https=)
AU (2) AU2018268400B2 (https=)
GB (1) GB201707864D0 (https=)
MX (2) MX2019013665A (https=)
NZ (1) NZ758037A (https=)
SG (1) SG11201909859RA (https=)
TW (1) TW201900176A (https=)
WO (1) WO2018211433A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55818A (fr) 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique
EP4347661A4 (en) * 2021-06-04 2025-06-18 ImmunoGen, Inc. TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA
WO2024097784A2 (en) * 2022-11-03 2024-05-10 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
KR20100043294A (ko) 2001-08-31 2010-04-28 비티지 인터내셔널 리미티드 항암제로서 사용되는 시클로펜타[ｇ]퀴나졸린 화합물
US7528141B2 (en) * 2001-08-31 2009-05-05 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
CN101977620B (zh) * 2008-03-18 2014-05-07 英国技术集团国际有限公司 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物
EA201291302A1 (ru) 2010-07-19 2013-09-30 Оникс Фармасьютикалз, Инк. Синтез циклопентахиназолинов
HUE028918T2 (en) 2010-12-22 2017-01-30 Btg Int Ltd Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt

Also Published As

Publication number Publication date
MX2019013665A (es) 2020-01-13
AU2018268400B2 (en) 2024-05-16
US20200197402A1 (en) 2020-06-25
AR111803A1 (es) 2019-08-21
MX2023005295A (es) 2023-05-24
JP2025098190A (ja) 2025-07-01
US20210252001A1 (en) 2021-08-19
JP2020519652A (ja) 2020-07-02
US12128045B2 (en) 2024-10-29
JP7627393B2 (ja) 2025-02-06
JP2023065427A (ja) 2023-05-12
US20250152587A1 (en) 2025-05-15
AU2024205462A1 (en) 2024-08-22
CA3062552A1 (en) 2018-11-22
CN110603042A (zh) 2019-12-20
EP3624803A1 (en) 2020-03-25
KR20200003811A (ko) 2020-01-10
US11026948B2 (en) 2021-06-08
AU2024205462B2 (en) 2025-09-25
KR20240148941A (ko) 2024-10-11
JP7658995B2 (ja) 2025-04-08
NZ758037A (en) 2026-01-30
WO2018211433A1 (en) 2018-11-22
US20200352945A1 (en) 2020-11-12
TW201900176A (zh) 2019-01-01
SG11201909859RA (en) 2019-11-28
AU2018268400A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PT3576740T (pt) Tratamento de cancro
IL263123A (en) Cancer treatments
IL259996A (en) Combinations for cancer treatment
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL247859A0 (en) Cancer treatment
IL274626A (en) Cancer treatment
ZA201707024B (en) Cancer treatment composition
IL260814A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL274748A (en) Improved cancer treatment
GB201522433D0 (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
GB201718985D0 (en) Treatment
GB201704909D0 (en) Cancer therapy
GB201819920D0 (en) Cancer treatment
GB201711855D0 (en) Cancer therapy
GB201713852D0 (en) Cancer treatment
GB201811431D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)